HR Execs on the Move

Odonate

www.odonate.com

 
Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.odonate.com
  • 4747 Executive Dr
    San Diego, CA USA 92121
  • Phone: 858.731.8180

Executives

Name Title Contact Details

Similar Companies

New England Peptide

New England Peptide is a Gardner, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dianthus Therapeutics

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

Aurora Biomed

Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

GenSpera

GenSpera, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Invivyd

Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.